Merck & Co licenses Kynapid for $700 million
This article was originally published in Scrip
Executive Summary
Merck & Co is to pay up to $700 million for worldwide rights to Cardiome Pharma's Kynapid (vernakalant), a novel investigational atrial fibrillation therapy.